A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
Study Details
Study Description
Brief Summary
This study will evaluate the effects of single ascending doses (SAD) and multiple ascending doses (MAD) of ALXN1830 administered subcutaneously (SC) to healthy adult participants.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
This Phase 1 study will consist of 3 SAD (Cohorts 1 to 3) and 4 MAD (Cohorts 4 to 7) cohorts. Participants will be randomly assigned in a 6:2 ratio to each of the 7 cohorts to receive either single or multiple doses of ALXN1830 (n = 6 per cohort) or single or multiple doses of placebo (n = 2 per cohort).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Cohort 1 Participants will receive a single SC dose of ALXN1830 or placebo (750 mg). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Experimental: Cohort 2 Participants will receive a single SC dose of ALXN1830 or placebo (1500 mg). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Experimental: Cohort 3 Participants will receive a single SC dose of ALXN1830 or placebo (2250 mg). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Experimental: Cohort 4 Participants will receive multiple SC doses of ALXN1830 or placebo (300 mg twice weekly; 8 doses total). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Experimental: Cohort 5 Participants will receive multiple SC doses of ALXN1830 or placebo (750 mg once weekly; 12 doses total). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Experimental: Cohort 6 Participants will receive multiple SC doses of ALXN1830 or placebo (1500 mg once weekly; 4 doses total). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Experimental: Cohort 7 Participants will receive multiple SC doses of ALXN1830 or placebo (2250 mg once weekly; 4 doses total). |
Drug: ALXN1830
ALXN1830 will be administered as SC infusion(s).
Drug: Placebo
Placebo will be administered as SC infusion(s).
|
Outcome Measures
Primary Outcome Measures
- Number Of Participants With Treatment-emergent Adverse Events [Day 1 through Day 141]
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. The incidence and severity of AEs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0).
Secondary Outcome Measures
- Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single And Multiple SC Doses Of ALXN1830 [Day 1 through Day 141]
Participants whole blood will be collected to assess the serum concentrations of ALXN1830.
- Maximum Observed Plasma Concentration (Cmax) Of Single And Multiple SC Doses Of ALXN1830 [Day 1 through Day 141]
Participants whole blood will be collected to assess the serum concentrations of ALXN1830.
- Change From Baseline In Serum Immunoglobulin G (IgG) Of Single And Multiple SC Doses Of ALXN1830 [Baseline to Day 141]
This outcome measure will assess the change in IgG level from venous blood samples, which is will be used to measure the anti FcRn PD activity of ALXN1830.
- Change From Baseline In Antidrug Antibody (ADA) And Neutralizing Antibody (Nab) Levels OF Single And Multiple Doses Of ALXN1830 [Baseline to Day 141]
Participants serum samples will be screened for ADA and Nab to further characterize the immunogenicity of ALXN1830.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Satisfactory medical assessment.
-
Participants must have had vaccination against pneumococcus (Pneumovax 23 [PPSV23]) at least 28 days, and maximally 4 years prior to Day 1.
-
Participants must have had seasonal influenza vaccination for the current season at least 28 days prior to Day 1.
-
Body weight within 50 to 90 kg, inclusive, and body mass index (BMI) within the range of 18 to 24.9 kg/m^2, inclusive.
-
Must be willing to follow protocol-specified contraception guidance during the study and for up to 3 months after last dose of study drug.
Exclusion Criteria:
-
Current/recurrent diseases or relevant medical history.
-
Known exposure to therapeutic proteins, such as monoclonal antibodies, including marketed drugs prior to dosing.
-
Participants who have prior exposure to ALXN1830.
-
Exposure to more than 4 new (small molecule) investigational compounds within 12 months prior to dosing.
-
Current enrollment or past participation within the last 90 days before signing of consent in this or any other interventional clinical study.
-
Presence of hepatitis B surface antigen (HBsAg) at Screening.
-
Positive hepatitis C antibody test result at Screening.
-
Positive human immunodeficiency virus (HIV) antibody test at Screening.
-
Participants who are either immunocompromised or have one of the following underlying medical conditions: anatomic or functional asplenia (including sickle cell disease); primary antibody deficiencies
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Clinical Trial Site | London | United Kingdom |
Sponsors and Collaborators
- Alexion Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ALXN1830-HV-105
- 2019-003496-18